JAN 24, 2019 10:34 AM PST

Drug Blocks Toxic-Protein Production in ALS

WRITTEN BY: Nouran Amin

Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in the production of toxic proteins that are associated with the development of ALS. Now, a new study aims to target a stress response with a known drug that may result in a decrease of toxic-protein production. "Both cellular stress and over-excitation eventually converge into the integrated stress response,” explains first author and graduate student, Thomas Westergard.

Learn more about ALS:

"Understanding what triggers toxic proteins production helped us hone in on drugs that could block them in laboratory tests," says co-senior author Aaron Haeusler, PhD, an Assistant Professor of Neuroscience within the Vickie & Jack Farber Institute for Neuroscience. Specifically, the researchers showed that the stress responses that trigger toxic protein production are similar to what happens during a seizure event.

The known drug used in the study is called ‘Trazodone’ and is currently approved for the treatment of depression and known to act on stress response. Trazodone was tested on models of the disease and was found to indeed inhibit toxic protein production of toxic protein in a cellular model contained the mutation. "This is a significant step forward in our collaborative approach," said co-author Dr. Piera Pasinelli, PhD, who lead the Jefferson Weinberg ALS Center. "Working together allowed us to speed up the research process getting from the identification of the "pathogenic stress" to testing a potentially useful drug. ALS is a complex and heterogenous disease that needs this collaborative approach, with each lab contributing its own expertise, to fill the gaps and to put together this complex puzzle in a systematic and efficient way.”

credit: healthiculture.com

Researchers are now looking forward to expand their studies for other compounds that might work better than trazodone. Results of the study were published in EMBO Molecular Medicine.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
OCT 19, 2021
Immunology
Reverse Vaccinations Tame the Immune System to Help Hemophilia Patients
OCT 19, 2021
Reverse Vaccinations Tame the Immune System to Help Hemophilia Patients
In patients with hemophilia A—a hereditary disorder where the blood cannot clot properly—their immune system ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
OCT 26, 2021
Microbiology
A Strategy to Improve the Efficacy of Antibiotics
OCT 26, 2021
A Strategy to Improve the Efficacy of Antibiotics
For many years, scientists and experts have warned about a building crisis - antibiotics are becoming less reliable, bac ...
OCT 27, 2021
Drug Discovery & Development
A novel drug delivery device to treat macular degeneration.
OCT 27, 2021
A novel drug delivery device to treat macular degeneration.
Last Friday, October 22nd, the United States Food and Drug Administration (FDA) approved a first of its kind d ...
OCT 28, 2021
Cannabis Sciences
What do Student Doctors and Medical Professionals Think of Cannabis?
OCT 28, 2021
What do Student Doctors and Medical Professionals Think of Cannabis?
In the current environment the legalization of cannabis, and its use for medicinal purposes, has been a divisive topic o ...
NOV 02, 2021
Coronavirus
COVID vaccines have saved 245,000 lives and counting
NOV 02, 2021
COVID vaccines have saved 245,000 lives and counting
What began in December 31, 2019 as a cluster of cases of pneumonia with an unknown etiology, quickly spread throughout t ...
Loading Comments...